-
AstraZeneca announces FDA approval of Epanova (omega-3-carboxylic acids)
WILMINGTON, Del. — AstraZeneca on Tuesday announced the Food and Drug Administration approved Epanova (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).
-
Greer Labs launches Oralair
LENOIR, N.C. — Greer Labs announced the launch and commmercial availability of Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass mixed pollens allergen extract) sublingual allergy immunotherapy tablets. The drug is used for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.